Study guide

5.1 Acute Kidney Injury & Glomerular Diseases

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

5.1 Acute Kidney Injury & Glomerular Diseases

Key Takeaways Explain This Topic AI

KDIGO AKI criteria require an increase in serum creatinine by ≥26.5 μmol/L within 48 hours, a ≥1.5-fold baseline increase within 7 days, or urine output <0.5 mL/kg/h for >6 consecutive hours.

Pre-renal azotemia is characterized by a fractional excretion of sodium (FENa) <1% and urine sodium <20 mmol/L, whereas intrinsic acute tubular necrosis (ATN) demonstrates FENa >2%, urine sodium >40 mmol/L, and muddy brown granular casts.

Nephrotic syndrome is defined by heavy proteinuria (>3.5 g/24h or urine protein-to-creatinine ratio >350 mg/mmol), hypoalbuminemia (<30 g/L), hyperlipidemia, and edema; nephritic syndrome features dysmorphic hematuria, red blood cell casts, hypertension, oliguria, and mild-to-moderate proteinuria (<3.0 g/24h).

Rapidly progressive glomerulonephritis (RPGN) causes acute renal failure over days to weeks with >50% crescent formation on renal biopsy, divided into anti-GBM (linear IgG deposition), immune complex (granular deposition), and pauci-immune ANCA-associated vasculitis (PR3/c-ANCA or MPO/p-ANCA).

IgA nephropathy typically presents with synpharyngitic macroscopic hematuria (1-2 days after upper respiratory tract infection) with normal serum C3/C4 levels, contrasting with post-streptococcal glomerulonephritis which manifests 2-4 weeks post-infection with low complement C3 levels.

Last updated: July 2026

Acute Kidney Injury & Glomerular Diseases

Acute kidney injury (AKI) is a clinical syndrome characterized by a rapid reduction in renal excretory function, resulting in the accumulation of nitrogenous waste products (uremia) and the dysregulation of extracellular fluid volume, electrolytes, and acid-base homeostasis. In hospital medicine, AKI occurs in approximately 15–20% of emergency admissions and up to 50% of patients in intensive care units.

KDIGO Definition & Staging System

The Kidney Disease: Improving Global Outcomes (KDIGO) consensus guidelines define AKI by the presence of any one of the following parameters:

Increase in serum creatinine by ≥ 26.5 μ mol/L \ge 26.5\,\mu\text{mol/L} ≥ 26.5 μ mol/L ( ≥ 0.3 mg/dL ≥ 0.3\,\text{mg/dL} ≥ 0.3 mg/dL ) within 48 hours.

Increase in serum creatinine to ≥ 1.5 \ge 1.5 ≥ 1.5 times baseline value within the prior 7 days.

Urine volume < 0.5 mL/kg/hour < 0.5\,\text{mL/kg/hour} < 0.5 mL/kg/hour for at least 6 consecutive hours.

KDIGO Stage Serum Creatinine Criteria Urine Output Criteria

Stage 1 1.5 – 1.9 × 1.5\text{--}1.9 \times 1.5 – 1.9 × baseline OR ≥ 26.5 μ mol/L \ge 26.5\,\mu\text{mol/L} ≥ 26.5 μ mol/L rise < 0.5 mL/kg/h < 0.5\,\text{mL/kg/h} < 0.5 mL/kg/h for 6–12 hours

Stage 2 2.0 – 2.9 × 2.0\text{--}2.9 \times 2.0 – 2.9 × baseline < 0.5 mL/kg/h < 0.5\,\text{mL/kg/h} < 0.5 mL/kg/h for ≥ 12 \ge 12 ≥ 12 hours

Stage 3 3.0 × 3.0 \times 3.0 × baseline OR serum creatinine ≥ 353.6 μ mol/L \ge 353.6\,\mu\text{mol/L} ≥ 353.6 μ mol/L OR initiation of RRT OR eGFR < 35 mL/min/1.73m 2 < 35\,\text{mL/min/1.73m}^2 < 35 mL/min/1.73m 2 in patients < 18 < 18 < 18 years < 0.3 mL/kg/h < 0.3\,\text{mL/kg/h} < 0.3 mL/kg/h for ≥ 24 \ge 24 ≥ 24 hours OR anuria for ≥ 12 \ge 12 ≥ 12 hours

Diagnostic Differentiation of AKI Etiologies

AKI is etiologically classified into three broad functional categories: Pre-renal azotemia , Intrinsic renal parenchymal disease , and Post-renal obstructive uropathy .

Pre-Renal vs. Intrinsic Acute Tubular Necrosis (ATN)

Pre-renal AKI stems from renal hypoperfusion without structural parenchymal injury. Under hypoperfusion, intact tubular function maximally reabsorbs water and sodium (driven by aldosterone and antidiuretic hormone). In contrast, acute tubular necrosis (ATN)—the predominant cause of intrinsic AKI in hospitalized adults resulting from prolonged ischemia or nephrotoxins—features tubular epithelial cell necrosis, loss of the brush border, and impaired sodium reabsorption.

Diagnostic Parameter Pre-Renal Azotemia Acute Tubular Necrosis (ATN)

Fractional Excretion of Na + \text{Na}^+ Na + ( FE Na \text{FE}_{\text{Na}} FE Na ​ ) < 1.0 % < 1.0\% < 1.0% > 2.0 % > 2.0\% > 2.0%

Fractional Excretion of Urea ( FE Urea \text{FE}_{\text{Urea}} FE Urea ​ ) (used if on diuretics) < 35 % < 35\% < 35% > 50 % > 50\% > 50%

Urinary Sodium Concentration < 20 mmol/L < 20\,\text{mmol/L} < 20 mmol/L > 40 mmol/L > 40\,\text{mmol/L} > 40 mmol/L

Urine Osmolality > 500 mOsm/kg > 500\,\text{mOsm/kg} > 500 mOsm/kg < 350 mOsm/kg < 350\,\text{mOsm/kg} < 350 mOsm/kg

Serum Urea to Creatinine Ratio > 100 : 1 > 100:1 > 100 : 1 (in μ mol / μ mol \mu\text{mol}/\mu\text{mol} μ mol / μ mol ) < 40 : 1 < 40:1 < 40 : 1

Urine Microscopy Sediment Normal / Hyaline casts Muddy brown granular casts, tubular epithelial cells

Exam Pearl: In patients taking loop or thiazide diuretics, FE Na \text{FE}_{\text{Na}} FE Na ​ is frequently elevated despite pre-renal hypoperfusion due to drug-induced natriuresis. In this clinical scenario, the Fractional Excretion of Urea ( FE Urea \text{FE}_{\text{Urea}} FE Urea ​ ) is the preferred diagnostic test; a value < 35 % < 35\% < 35% confirms pre-renal azotemia.

Acute Interstitial Nephritis (AIN)

AIN is an immune-mediated hypersensitivity reaction involving the renal interstitium, accounting for up to 15% of unexplained intrinsic AKI.

Etiologies : Drugs cause > 75 % > 75\% > 75% of cases—notably NSAIDs, penicillins, cephalosporins, fluoroquinolones, proton pump inhibitors (PPIs), sulfonamides, and allopurinol. Autoimmune causes include Sjogren syndrome and sarcoidosis.

Clinical Presentation : The classic clinical triad of fever, maculopapular rash, and peripheral eosinophilia is present in only 10–30% of patients.

Urinary Findings : Sterile pyuria, white blood cell (WBC) casts, eosinophiluria (Hansel stain), and mild sub-nephrotic proteinuria.

Glomerular Diseases: Nephrotic vs. Nephritic Syndromes

Glomerulonephritis represents immune-mediated inflammatory or non-inflammatory disruption of the glomerular filtration barrier.

Feature Nephrotic Syndrome Nephritic Syndrome

Primary Pathology Podocyte / epithelial cell injury resulting in charge/size selectivity loss Endothelial / mesangial inflammatory breakdown and hypercellularity

Proteinuria Heavy: > 3.5 g/24h > 3.5\,\text{g/24h} > 3.5 g/24h (PCR > 350 mg/mmol > 350\,\text{mg/mmol} > 350 mg/mmol ) Sub-nephrotic: < 3.0 g/24h < 3.0\,\text{g/24h} < 3.0 g/24h

  • Serum Albumin Hypoalbuminemia ( < 30 g/L < 30\,\text{g/L} < 30 g/L ) Normal or mildly reduced
  • Edema Marked peripheral edema, anasarca Mild dependent edema, periorbital edema

Hematuria Absent or microscopic without dysmorphism Macroscopic / microscopic with dysmorphic RBCs and RBC casts

Blood Pressure Usually normal (hypovolemic activation of RAAS) Elevated / Severe hypertension (salt and water retention)

  • Renal Function eGFR preserved initially (except late stage) Acute rise in creatinine, oliguria
  • Major Causes of Nephrotic Syndrome

Minimal Change Disease : Responsible for 80% of nephrotic syndrome in children and 10–15% in adults. Light microscopy shows normal glomeruli; electron microscopy reveals diffuse foot process effacement (podocytopathy). Excellent response to corticosteroids.

Focal Segmental Glomerulosclerosis (FSGS) : Commonest cause in adults of African descent. Associated with APOL1 risk alleles, HIV infection, obesity, and heroin use. Light microscopy demonstrates segmental sclerosis in < 50 % < 50\% < 50% of glomeruli. High rate of steroid resistance and progression to end-stage renal disease (ESRD).

Membranous Nephropathy : Primary form accounts for 70% of adult cases, driven by autoantibodies against the Phospholipase A2 Receptor (PLA2R) . Secondary causes include solid organ malignancies (lung, colon, breast), hepatitis B/C, NSAIDs, and SLE (Class V). Light microscopy displays diffuse capillary wall thickening; silver stain shows subepithelial "spike and dome" projections.

Renal Amyloidosis : Deposition of AL (light chain) or AA (serum amyloid A) fibrils. Biopsy confirms apple-green birefringence under polarized light after Congo red staining.

Major Causes of Nephritic Syndrome

IgA Nephropathy (Berger Disease) : The commonest primary glomerulonephritis worldwide. Characterized by synpharyngitic macroscopic hematuria developing 1–2 days after an upper respiratory or gastrointestinal infection. Immunofluorescence demonstrates mesangial IgA deposition. Serum C3 and C4 levels remain normal .

Post-Streptococcal Glomerulonephritis (PSGN) : Occurs 2–4 weeks following Group A β \beta β -hemolytic streptococcal pharyngitis or impetigo (due to nephritogenic strains with SpeB/NAPI antigens). Features low serum complement C3, elevated anti-streptolysin O (ASO) or anti-DNase B titers. Electron microscopy shows classic subepithelial "humps".

Rapidly Progressive Glomerulonephritis (RPGN) : A nephrological emergency characterized by rapid loss of renal function over days to weeks with crescent formation in > 50 % > 50\% > 50% of glomeruli on biopsy.

RPGN Subtype Pathogenetic Mechanism Key Diagnostic Biomarkers Biopsy Immunofluorescence

Type 1: Anti-GBM Disease Autoantibodies against α 3 \alpha_3 α 3 ​ chain of type IV collagen Anti-GBM antibodies positive Smooth, linear IgG deposition along basement membrane

Type 2: Immune Complex Deposition of circulating antigen-antibody complexes Low C3/C4, positive ANA/dsDNA, ASO, cryoglobulins Granular "lumpy bumpy" immune complex deposition

Type 3: Pauci-Immune ANCA-associated small vessel vasculitis (GPA, MPA, EGPA) c-ANCA (PR3-ANCA) or p-ANCA (MPO-ANCA) positive Negative or minimal immune deposition ("pauci-immune")

Exam Pearl: Distinguishing IgA Nephropathy from PSGN is a classic MRCPI Part I question:

IgA Nephropathy : Synpharyngitic onset (1–2 days post-URI), normal serum complement levels.

PSGN : Post-infectious delay (2–4 weeks post-strep), transiently depressed serum complement C3 level that normalizes within 6–8 weeks.